We manufacture clinical-grade pluripotent stem cells

The potential of cell therapies for hard-to-treat conditions has been limited by the complex and costly logistics of autologous treatments. Therapy cells are produced “from the patient, for the patient.”

Off-the-shelf, allogeneic approaches – where treatments are manufactured from a healthy donor’s cells and used for multiple patients – have moved into the spotlight as a way to accelerate time-to-patient and reduce cost significantly. Boosting immune compatibility of donor cells and ensuring their fit for therapeutic purposes is critical to realize such advanced therapy medicinal products.

This is where RHEINCELL excels.

We produce GMP-grade human induced pluripotent stem cells (iPSCs) from a unique source of clinically-approved, donor-consented umbilical cord blood units. Furthermore, we expedite allogeneic approaches with a collection of HLA-homozygous iPSCs that reduce transplant rejection. Partnering with innovative developers of off-the-shelf iPSC-based therapies, we advance cell therapies where they begin: at the cell.

Have a look at
what we do

This website uses cookies to provide the best possible functionality. Find out more in our privacy policy.